Contributions
Abstract: P1614
Type: LB Poster
Abstract Category: Late Breaking News
Background: GNbAC1, a humanized monoclonal antibody, is an innovative treatment currently in development for multiple sclerosis (MS) which, contrary to the immunomodulation / immunosuppressive mechanism of action of most of the MS drugs, targets specifically the envelope protein of the Multiple Sclerosis associated RevtroVirus (MSRV-Env), a protein of endogenous retroviral origin supposed to be critical in MS pathogenesis.
Methods: This trial is a randomized placebo controlled 4-arm study with the objective of demonstrating the efficacy of repeated doses of GNbAC1 on the cumulative number of new T1 Gadolinium-enhancing lesions measured from Week 12 to 24 in patients with relapsing remitting MS (RRMS). Two hundred sixty patients with RRMS are planned to be included. Three doses of GNbAC1 will be tested versus placebo: 6 mg/kg, 12 mg/kg and 18 mg/kg, administered intravenously, with 4-week administration intervals. The design is based on the classic 24-week placebo-controlled repeated brain MRI trial design (Period 1), with an extension of 24 weeks during which placebo patients will be re-randomized to one of the three doses of GNbAC1 to assess efficacy and safety of prolonged treatment of GNbAC1 (Period 2). The primary endpoint is the cumulative number of new Gadolinium enhanced T1 lesions measured using repeated brain magnetic resonance imaging (MRI) scans from Week 12 to 24; secondary endpoints, including additional MRI and clinical endpoints, will be assessed at the end of both Periods 1 and 2. Pharmacokinetics and biomarkers will be assessed in serum in all patients at several time points and also in cerebrospinal fluid in a subgroup of patients. To alleviate potential ethical concerns regarding placebo administration in MS, an early escape from the trial at the discretion of the investigator will be implemented for patients with a worsening clinical condition during trial.
The study started in May 2016 and recruitment is actively progressing. Period 1 results are expected for 2017.
Conclusion: This dose-finding study will provide the first efficacy data of an innovative therapeutic approach for MS. The constraints of using a placebo group in RRMS patients while optimizing the trial power to evidence a new mechanism of action is discussed and recruitment status is presented.
Disclosure: RG, FC, HP, VV and CB are employees of GeNeuro SA; FC, and CB are shareholders of GeNeuro SA. HMS, MLA and EL are employees of Servier. HPH has received honoraria from GeNeuro SA and Servier.
Abstract: P1614
Type: LB Poster
Abstract Category: Late Breaking News
Background: GNbAC1, a humanized monoclonal antibody, is an innovative treatment currently in development for multiple sclerosis (MS) which, contrary to the immunomodulation / immunosuppressive mechanism of action of most of the MS drugs, targets specifically the envelope protein of the Multiple Sclerosis associated RevtroVirus (MSRV-Env), a protein of endogenous retroviral origin supposed to be critical in MS pathogenesis.
Methods: This trial is a randomized placebo controlled 4-arm study with the objective of demonstrating the efficacy of repeated doses of GNbAC1 on the cumulative number of new T1 Gadolinium-enhancing lesions measured from Week 12 to 24 in patients with relapsing remitting MS (RRMS). Two hundred sixty patients with RRMS are planned to be included. Three doses of GNbAC1 will be tested versus placebo: 6 mg/kg, 12 mg/kg and 18 mg/kg, administered intravenously, with 4-week administration intervals. The design is based on the classic 24-week placebo-controlled repeated brain MRI trial design (Period 1), with an extension of 24 weeks during which placebo patients will be re-randomized to one of the three doses of GNbAC1 to assess efficacy and safety of prolonged treatment of GNbAC1 (Period 2). The primary endpoint is the cumulative number of new Gadolinium enhanced T1 lesions measured using repeated brain magnetic resonance imaging (MRI) scans from Week 12 to 24; secondary endpoints, including additional MRI and clinical endpoints, will be assessed at the end of both Periods 1 and 2. Pharmacokinetics and biomarkers will be assessed in serum in all patients at several time points and also in cerebrospinal fluid in a subgroup of patients. To alleviate potential ethical concerns regarding placebo administration in MS, an early escape from the trial at the discretion of the investigator will be implemented for patients with a worsening clinical condition during trial.
The study started in May 2016 and recruitment is actively progressing. Period 1 results are expected for 2017.
Conclusion: This dose-finding study will provide the first efficacy data of an innovative therapeutic approach for MS. The constraints of using a placebo group in RRMS patients while optimizing the trial power to evidence a new mechanism of action is discussed and recruitment status is presented.
Disclosure: RG, FC, HP, VV and CB are employees of GeNeuro SA; FC, and CB are shareholders of GeNeuro SA. HMS, MLA and EL are employees of Servier. HPH has received honoraria from GeNeuro SA and Servier.